Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 12/20 | 1.00 |
| ▸ | MMP2 | P08253 | 9/20 | 1.00 |
| ▸ | MMP9 | P14780 | 9/20 | 1.00 |
| ▸ | MMP1 | P03956 | 6/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | MMP7 | P09237 | 2/20 | 1.00 |
| ▸ | MMP8 | P22894 | 2/20 | 1.00 |
| ▸ | MMP13 | P45452 | 2/20 | 1.00 |
| ▸ | MMP14 | P50281 | 2/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966106 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL10052499 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL6692506 | 1.00 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL5926082 | 0.91 | ADAM17 (0.84) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL5926083 | 0.91 | ADAM17 (0.84) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL5926034 | 0.91 | ADAM17 (0.83) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL21823203 | 0.90 | ADAM17 (0.81) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL4202178 | 0.90 | MMP2 (0.81) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL4197086 | 0.87 | MMP2 (0.78) | ADAM17MMP2MMP9MMP1MMP3 | |
| SCHEMBL5926078 | 0.87 | ADAM17 (0.77) | ADAM17MMP2MMP9MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | claimed |
| EP-2160606-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | Galderma Research & Development (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2009004247-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | WO | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| US-20210393632-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | UNIVERSITÉ PARIS CITÉ (FR) | 2021-12-23 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | ADAM17 22/4885MMP2 60/4885MMP9 21/4885 |
| US-20210393632-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | MAP3K3, GRK3, TAS1R3 | ADAM17 4276/4885MMP2 4394/4885MMP9 4188/4885 |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | ADAM17 11/4885MMP2 7/4885MMP9 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.